Cargando…

Apoptosis, ageing and cancer susceptibility

We have previously shown that peripheral blood lymphocytes (PBL) from individuals carrying a germline TP53 mutation show a dramatically reduced apoptotic response to radiation. As part of a study of this phenomenon, we also investigated apoptotic response in a series of breast cancer patients lackin...

Descripción completa

Detalles Bibliográficos
Autores principales: Camplejohn, R S, Gilchrist, R, Easton, D, McKenzie-Edwards, E, Barnes, D M, Eccles, D M, Ardern-Jones, A, Hodgson, S V, Duddy, P M, Eeles, R A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377171/
https://www.ncbi.nlm.nih.gov/pubmed/12592359
http://dx.doi.org/10.1038/sj.bjc.6600767
_version_ 1782154793826910208
author Camplejohn, R S
Gilchrist, R
Easton, D
McKenzie-Edwards, E
Barnes, D M
Eccles, D M
Ardern-Jones, A
Hodgson, S V
Duddy, P M
Eeles, R A
author_facet Camplejohn, R S
Gilchrist, R
Easton, D
McKenzie-Edwards, E
Barnes, D M
Eccles, D M
Ardern-Jones, A
Hodgson, S V
Duddy, P M
Eeles, R A
author_sort Camplejohn, R S
collection PubMed
description We have previously shown that peripheral blood lymphocytes (PBL) from individuals carrying a germline TP53 mutation show a dramatically reduced apoptotic response to radiation. As part of a study of this phenomenon, we also investigated apoptotic response in a series of breast cancer patients lacking TP53 mutations and in a control group of individuals without cancer. There was a significant reduction in mean apoptotic response with increasing age in all groups. These findings are consistent with a number of studies in rodents, which have demonstrated a reduction in DNA damage-induced apoptosis with increasing age. In addition, after adjusting for age, breast cancer patients showed significantly reduced apoptotic responses compared with normal controls (P=0.002). The odds ratio for breast cancer in women with an apoptotic response of <35%, compared with women with a response of >49%, was 6.42 (95% CI 1.68–24.6). The data further support the hypothesis that a reduction in apoptotic response to DNA damage with increasing age may play a significant role in the age-related increase in cancer.
format Text
id pubmed-2377171
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23771712009-09-10 Apoptosis, ageing and cancer susceptibility Camplejohn, R S Gilchrist, R Easton, D McKenzie-Edwards, E Barnes, D M Eccles, D M Ardern-Jones, A Hodgson, S V Duddy, P M Eeles, R A Br J Cancer Clinical We have previously shown that peripheral blood lymphocytes (PBL) from individuals carrying a germline TP53 mutation show a dramatically reduced apoptotic response to radiation. As part of a study of this phenomenon, we also investigated apoptotic response in a series of breast cancer patients lacking TP53 mutations and in a control group of individuals without cancer. There was a significant reduction in mean apoptotic response with increasing age in all groups. These findings are consistent with a number of studies in rodents, which have demonstrated a reduction in DNA damage-induced apoptosis with increasing age. In addition, after adjusting for age, breast cancer patients showed significantly reduced apoptotic responses compared with normal controls (P=0.002). The odds ratio for breast cancer in women with an apoptotic response of <35%, compared with women with a response of >49%, was 6.42 (95% CI 1.68–24.6). The data further support the hypothesis that a reduction in apoptotic response to DNA damage with increasing age may play a significant role in the age-related increase in cancer. Nature Publishing Group 2003-02-24 2003-02-18 /pmc/articles/PMC2377171/ /pubmed/12592359 http://dx.doi.org/10.1038/sj.bjc.6600767 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Camplejohn, R S
Gilchrist, R
Easton, D
McKenzie-Edwards, E
Barnes, D M
Eccles, D M
Ardern-Jones, A
Hodgson, S V
Duddy, P M
Eeles, R A
Apoptosis, ageing and cancer susceptibility
title Apoptosis, ageing and cancer susceptibility
title_full Apoptosis, ageing and cancer susceptibility
title_fullStr Apoptosis, ageing and cancer susceptibility
title_full_unstemmed Apoptosis, ageing and cancer susceptibility
title_short Apoptosis, ageing and cancer susceptibility
title_sort apoptosis, ageing and cancer susceptibility
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377171/
https://www.ncbi.nlm.nih.gov/pubmed/12592359
http://dx.doi.org/10.1038/sj.bjc.6600767
work_keys_str_mv AT camplejohnrs apoptosisageingandcancersusceptibility
AT gilchristr apoptosisageingandcancersusceptibility
AT eastond apoptosisageingandcancersusceptibility
AT mckenzieedwardse apoptosisageingandcancersusceptibility
AT barnesdm apoptosisageingandcancersusceptibility
AT ecclesdm apoptosisageingandcancersusceptibility
AT ardernjonesa apoptosisageingandcancersusceptibility
AT hodgsonsv apoptosisageingandcancersusceptibility
AT duddypm apoptosisageingandcancersusceptibility
AT eelesra apoptosisageingandcancersusceptibility